Tarbox Family Office, Inc. Vertex Pharmaceuticals Inc Transaction History

Tarbox Family Office, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 19, 2022	SELL	$234.96 - $292.55 $37,593 - $46,808	-160 Closed	0 $0
Q1 2022 Apr 25, 2022	SELL	$221.42 - $260.97 $11,735 - $13,831	-53 Reduced 24.88%	160 $42,000
Q4 2021 Jan 06, 2022	BUY	$177.01 - $223.45 $4,956 - $6,256	28 Added 15.14%	213 $47,000
Q3 2021 Oct 12, 2021	BUY	$181.39 - $202.99 $4,534 - $5,074	25 Added 15.63%	185 $34,000
Q4 2020 Jan 27, 2021	SELL	$207.01 - $276.09 $8,901 - $11,871	-43 Reduced 21.18%	160 $38,000
Q3 2020 Oct 22, 2020	SELL	$255.65 - $303.1 $32,723 - $38,796	-128 Reduced 38.67%	203 $55,000
Q2 2020 Jul 23, 2020	BUY	$225.48 - $295.8 $2,705 - $3,549	12 Added 3.76%	331 $96,000
Q4 2019 Jan 31, 2020	BUY	$166.71 - $223.91 $500 - $671	3 Added 0.95%	319 $70,000
Q2 2019 Aug 02, 2019	BUY	$164.61 - $190.37 $1,646 - $1,903	10 Added 3.27%	316 $58,000
Q4 2018 Feb 01, 2019	BUY	$151.91 - $192.21 $1,822 - $2,306	12 Added 4.08%	306 $51,000
Q4 2017 Jan 29, 2018	BUY	$137.28 - $155.55 $5,491 - $6,222	40 Added 15.75%	294 $44,000
Q3 2017 Oct 19, 2017	BUY	$148.13 - $162.24 $37,625 - $41,208	254	254 $39,000

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Tarbox Family Office, Inc., based on Form 13F filings with the SEC.

Stay updated on Tarbox Family Office, Inc. with notifications on news.